Share
Dr. Yasmine Wasfi
Savara Inc., a clinical-stage biopharmaceutical company dedicated to developing therapies for rare respiratory diseases, has appointed Yasmine Wasfi, M.D., Ph.D., FCCP, as Chief Medical Officer (CMO).
She succeeds Ray Pratt, M.D., FACP, who will transition to the role of Senior Medical Advisor.
In her new position, Dr. Wasfi will report directly to the company’s Chair and Chief Executive Officer and join Savara’s executive leadership team. Previously serving as Executive Vice President, Head of Clinical Development and Clinical Operations, Dr. Wasfi has played a pivotal role in advancing Savara’s clinical programs and driving strategic development efforts.
With extensive experience in clinical research and drug development, Dr. Wasfi’s career spans both large pharmaceutical and biotechnology companies, including Amicus Therapeutics, Johnson & Johnson, and Merck. Her expertise covers the development of large and small molecule therapeutics, with particular focus on respiratory and late-phase immunology programs.
Dr. Wasfi earned her B.A. in Biology from the University of Delaware, M.D. from the University of Pennsylvania School of Medicine, and Ph.D. in Clinical Science from the University of Colorado Health Sciences Center. She completed her internship and residency in internal medicine at the Hospital of the University of Pennsylvania, followed by a fellowship in Pulmonary and Critical Care at the University of Colorado Health Sciences Center.
Her appointment reinforces Savara’s commitment to advancing innovative therapies and strengthening its leadership team in the pursuit of transformative treatments for patients with rare lung diseases.
